Investing.com -- Evommune Inc. (NYSE:EVMN) stock soared 64% after the clinical-stage biotechnology company announced positive top-line results from its Phase 2a trial evaluating EVO301 in patients ...
The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in ...
Investing.com -- Aquestive Therapeutics (NASDAQ:AQST) stock rose 18% Monday despite the company announcing it received a complete response letter (CRL) from the U.S. Food and Drug Administration for ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...
SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the initiation ...
Department of Radiation Oncology, General Hospital of Northern Theater Command, Shenyang, China Background: Accurate dose calculation algorithms are critical for optimizing radiotherapy outcomes. This ...
A single intravenous dose of etranacogene dezaparvovec gene therapy maintained factor IX (FIX) activity at 45.7 IU/dL after 5 years in patients with hemophilia B, eliminating the need for prophylaxis ...
Purpose: To investigate the feasibility of proton therapy planning using stopping power ratio (SPR) maps directly generated from spectral CT raw data, and to perform a comparative evaluation of dose ...
Anemia during pregnancy is a common occurrence and often due to iron deficiency. It is a global public health problem, affecting an estimated 37 percent of pregnant individuals, according to the World ...
CINCINNATI (WKRC) — High doses of vitamins administered intravenously are becoming a popular method to aid recovery after surgery, according to health professionals. This approach involves customizing ...
Extension for Community Healthcare Outcomes-Palliative Care in Africa and Quality of Life, Symptoms, Patient Experience, and Caregiver Distress Among Patients With Cancer This phase II randomized ...
Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple myeloma patients. The IRAKLIA study enrolled 532 patients globally, ...